Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest regarding a broad scope of topics are abstracted monthly.
Get full access to this article
View all access options for this article.
References
1.
GrankoR.P.PoppeL.B.DanielsR.Managing peak performers. Am J Health Syst Pharm.2012; 69(4): 282–284.
2.
GriffithM.M.GrossA.E.SuttonS.H.The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. Clin Infect Dis.2012; 54(5): 684–691.
3.
HaasC.E.EckelS.ArifS.BeringerP.M.Acute care clinical pharmacy practice: unit- versus service-based models. Pharmacotherapy.2012; 32(2): e35–e44.
4.
KnappD.A.Pharmacy school provenance and pharmacy practice. Pharmacotherapy.2012; 32(2): 99–102.
5.
LeF.AroraV.ShahD.N.A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy.2012; 32(2): 129–134.
6.
SmithJ.M.Potential role of pharmacy students on hospital cardiopulmonary resuscitation response teams. Am J Health Syst Pharm.2012; 69(5): 369–370.
7.
Thompson-MooreN.LieblM.G.Health care system vulnerabilities: understanding the root causes of patient harm. Am J Health Syst Pharm.2012; 69(5): 431–436.
8.
WhiteA.M.AlbertsonB.MunceyL.Development and implementation of a clinical pharmacist training and assessment program. Am J Health Syst Pharm.2012; 69(4): 278–281.
9.
YoonD.ParkM.Y.ChoiN.K.Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm. Clin Pharmacol Ther.2012; 91(3): 467–474.
10.
AlpertJ.S.New directions in anticoagulation. Am J Med.2012; 125(3): 217–218.
11.
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic therapy and prevention of thrombosis, 9th ed. Chest.2012; 141(2 suppl): 1s–801s.
12.
AntoonsG.WillemsR.SipidoK.R.Alternative strategies in arrhythmia therapy: evaluation of Na/Ca exchange as an antiarrhythmic target. Pharmacol Ther.2012; 134(1): 26–42.
13.
LaviS.CantorW.J.CasanovaA.Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: insights from the TRANSFER-AMI trial. Am Heart J.2012; 163(2): 176–181.
14.
RitterJ.M.Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol.2012; 73(3): 331–334.
15.
BozekJ.ZimmermanS.Does the administration of anti-fibrinolytic drugs in acute trauma reduce mortality?Ann Emerg Med.2012; 59(3): 223–224.
16.
CerianiE.RusconiA.M., Gruppo di Autoformazione Metodologica (GrAM). Timing of the initiation of parenteral nutrition in critically ill adults. Intern Emerg Med.2012; 7(1): 75–76.
17.
YoungJ.A.Pharmacotherapy for traumatic brain injury: focus on sympathomimetics. Pharmacol Ther.2012; 134(1): 1–7.
18.
BronskillS.E.GillS.S.PatersonJ.M.Exploring variation in rates of polypharmacy across long term care homes. J Am Med Dir Assoc.2012; 13(3): 309.e15–309.e21.
19.
GnjidicD.HilmerS.N.BlythF.M.High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther.2012; 91(3): 521–528.
20.
LynchJ.E.HendersonN.R.RamageL.Association between statin medication use and improved outcomes during inpatient rehabilitation in older people. Age Ageing2012; 41(2): 260–262.
21.
SaariT.I.IhmsenH.NeuvonenP.J.Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth.2012; 108(3): 491–498.
22.
ThorpeC.T.LassilaH.C.O'NeilC.K.Reconsideration of key articles regarding medication-related problems in older adults from 2011. Am J Geriatr Pharmacother.2012; 10(1): 2–13.
23.
CattoirV.Actinobaculum schaalii: review of an emerging uropathogen. J Infect.2012; 64(3): 260–267.
24.
DancerS.J.Infection control “undercover”: a patient experience. J Hosp Infect.2012; 80(3): 189–191.
25.
GouldI.M.Vancomycin minimum inhibitory concentrations and outcome in patients with severe Staphylococcus aureus infection. J Infect Dis.2012; 205(5): 864–865.
26.
HootonT.M.RobertsP.L.StapletonA.E.Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA.2012; 307(6): 583–589.
27.
NicholsonS.C.WeiteT.FileT.M.JrA randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents.2012; 39(3): 240–246.
28.
WisplinghoffH.PaulusT.LugenheimM.Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii, and Acinetobacter nosocomialis in the United States. J Infect.2012; 64(3): 282–290.
29.
EarleyA.MiskulinD.LambE.J.Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review [published online ahead of print February 6, 2012]. Ann Intern Med.
30.
EdwardsN.C.SteedsR.P.ChueC.D.The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol.2012; 73(3): 447–454.
31.
DalrympleL.S.KatzR.KestenbaumB.The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis.2012; 59(3): 356–363.
32.
GiinebakmazO.KayaM.G.KocF.Does nebivolol prevent contrast-induced nephropathy in humans? [published online ahead of print January 19, 2012]. Clin Cardiol.
33.
NelsonW.K.FormicaR.N.JrCooperD.L.An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers [published online ahead of print February 13, 2012]. J Oncol Pharm Pract.
34.
PatelM.ThimonsD.G.WinstonJ.L.An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. J Am Med Dir Assoc.2012; 13(3): 244–248.
35.
ThadhaniR.AppelbaumE.PritchettY.Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA.2012; 307(7): 674–684.
36.
BramnessJ.G.FuruK.SkurtveitS.EngelandA.Effect of the market withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Ther.2012; 91(3): 438–441.
37.
DienerH.C.EikelboomJ.ConnollyS.J.for the AVERROES steering committee and investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol.2012; 11(3): 225–231.
38.
SilbergleitR.DurkalskiV.LowensteinD.; for the NETT Investigators. Intramuscular versus intravenous therapy for pre-hospital status epilepticus. N Engl J Med2012; 366(7): 591–600.
WagnerG.IcksA.AbholzH.H.Antihypertensive treatment and risk of dementia: a retrospective database study. Int J Clin Pharmacol Ther.2012; 50(3): 195–201.
42.
BaselgaJ.BradburyI.EidtmannH.on behalf of the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet.2012; 379(9816): 633–640.
43.
ConticelloC.MartinettiD.AdamoL.Disulfiram, an old drug with new potential therapeutic uses for human haematological malignancies [published online ahead of print February 9, 2012]. Int J Cancer.
44.
FischerJRGriesingerF.FinkT.Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—results of the nonrandomised phase II study TaxErb. Lung Cancer.2012; 75(3): 348–352.
45.
WilsonJ.Al-NaeebA.B.RazakA.R.Clinical outcomes of a phase II open-labelled, randomised study investigating the tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone naive high risk/metastatic prostate cancer. Clin Oncol.2012; 24(2): 156–157.
46.
CoberM.P.KilluG.BrattainA.Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr.2012; 160(3): 421–427.
47.
El-HefnawyA.S.HelmyT.El-AssmyM.M.Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. Urology.2012; 79(2): 428–433.
48.
PurdyJ.JouveS.YanJ.L.Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther.2012; 34(2): 496–507.e1.
49.
HagiharaM.UmemuraT.KimuraM.Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother.2012; 18(1): 10–16.
50.
HomeP.The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences [published online ahead of print February 9, 2012]. Diabetes Obes Metab.
51.
MarinoS.E.BirnbaumA.K.LeppikI.E.Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther.2012; 91(3): 483–488.
